Symbiotec Pharmalab Limited IPO – Details, Price, Dates, Lot Size, Financials, Strengths and Risks
Symbiotec Pharmalab Limited IPO is the public offering of Symbiotec Pharmalab Ltd., a research-focused pharmaceutical and biotechnology company with expertise in active pharmaceutical ingredients (APIs), corticosteroids, steroidal hormones, contract development and manufacturing organization (CDMO) services, and complex injectable products.
With more than three decades of industry experience, Symbiotec has developed an integrated pharmaceutical manufacturing platform combining fermentation, biosynthesis, biotransformation, and chemical synthesis. The company supplies products to customers across domestic and international markets and has established capabilities supported by global regulatory approvals.
About Symbiotec Pharmalab Limited IPO
Symbiotec Pharmalab operates across three primary business segments: API products, CDMO services, and complex injectables. Its portfolio includes more than 60 corticosteroid and steroidal-hormone APIs, covering products such as Hydrocortisone, Betamethasone, Methylprednisolone, Progesterone, Estrogen, and Testosterone.
The company follows a vertically integrated farm/microbe-to-pharmacy model, allowing it to manufacture important starting materials internally. This approach can reduce dependency on external suppliers while providing greater control over manufacturing processes and product quality.
As of March 31, 2026, the company operated manufacturing facilities at Rau, Pithampur, Ujjain, and Mhow in Madhya Pradesh. Its manufacturing infrastructure included 584.67 MT of chemical synthesis capacity and 700 KL of fermentation capacity. It also had an annual capacity of approximately 20 million complex injectable vials.
Symbiotec serves more than 200 customers across over 40 countries. International markets contributed approximately 67.04% of revenue from operations during Fiscal 2026, highlighting the company’s significant exposure to global pharmaceutical markets.
Symbiotec Pharmalab IPO Details
The Symbiotec Pharmalab Limited IPO is structured as a book-built issue comprising both a fresh issue and an offer for sale.
| Particulars | Details |
|---|---|
| IPO Opening Date | 24 August 2026 |
| IPO Closing Date | 27 August 2026 |
| Issue Type | Book Built Issue |
| Total Issue Size | 1,77,86,442 Shares worth ₹1,757 Crore |
| Fresh Issue | 15,21,261 Shares worth ₹150 Crore |
| Offer for Sale | 1,62,65,181 Shares worth ₹1,607 Crore |
| Face Value | ₹2 per share |
| IPO Price Band | ₹933 – ₹988 per share |
| Market Lot | 15 Shares |
| Minimum Investment | 15 Shares – 1 Lot |
| Employee Discount | ₹90 |
| Listing | BSE and NSE |
| Registrar | MUFG Intime India Private Limited |
| QIB Portion | 50% |
| NII Portion | 15% |
| Retail Portion | 35% |
Symbiotec Pharmalab IPO Date Schedule
Investors interested in the issue can refer to the following important dates:
| IPO Activity | Date |
|---|---|
| IPO Open Date | 24 August 2026 |
| IPO Close Date | 27 August 2026 |
| Basis of Allotment | 28 August 2026 |
| Initiation of Refund | 31 August 2026 |
| Credit of Shares to Demat Account | 31 August 2026 |
| IPO Listing Date | 1 September 2026 |
| UPI Mandate Confirmation Cut-off | 5 PM, 27 August 2026 |
Symbiotec Pharmalab IPO Lot Size and Investment
At the upper price band of ₹988 per share, investors can calculate their application amount based on the applicable lot size.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 15 | ₹14,820 |
| Retail Maximum | 13 | 195 | ₹1,92,660 |
| S-HNI Minimum | 14 | 210 | ₹2,07,480 |
| S-HNI Maximum | 67 | 1,005 | ₹9,92,940 |
| B-HNI Minimum | 68 | 1,020 | ₹10,07,760 |
Competitive Strengths of Symbiotec Pharmalab
Symbiotec has developed several business strengths that support its position in the pharmaceutical industry.
Strong portfolio of more than 60 corticosteroid and steroidal-hormone APIs.
Established presence across more than 40 international markets.
Long-standing relationships with domestic and overseas customers.
Vertically integrated manufacturing capabilities.
Strong research and development capabilities.
Expansion into CDMO services and complex injectable products.
Manufacturing infrastructure supported by regulatory approvals.
Experience spanning more than 30 years in pharmaceutical manufacturing.
The company’s backward integration and technical capabilities may help it manage manufacturing requirements while supporting the development of specialized pharmaceutical products.
Symbiotec Pharmalab IPO Financial Performance
The company has reported steady revenue growth along with profitability over the past three financial years.
| Financial Year | Total Revenue | Total Expense | Profit After Tax | Total Borrowing |
|---|---|---|---|---|
| 31 March 2024 | ₹723.33 Cr | ₹590.99 Cr | ₹100.06 Cr | ₹247.21 Cr |
| 31 March 2025 | ₹755.98 Cr | ₹608.85 Cr | ₹96.79 Cr | ₹540.92 Cr |
| 31 March 2026 | ₹872.26 Cr | ₹709.90 Cr | ₹109.90 Cr | ₹387.91 Cr |
Amount in ₹ Crore.
For March 31, 2026, the company reported ROE of 11.19%, ROCE of 11.56%, RoNW of 9.48%, PAT margin of 12.60%, EBITDA margin of 26.59%, and NAV of ₹184.69.
The reported pre-IPO EPS was ₹17.82, while post-IPO EPS was ₹17.39. The pre-IPO P/E stood at 55.44 times compared with 56.81 times on a post-IPO basis.
Objects of the Issue
A portion of the fresh issue proceeds is proposed to be used for reducing the company’s outstanding borrowings.
| Purpose | Expected Amount |
|---|---|
| Prepayment/repayment of outstanding borrowings | ₹112.50 Crore |
| General Corporate Purposes | As applicable |
Reducing borrowings can potentially strengthen the company’s financial position and provide greater flexibility for future business operations.
Symbiotec Pharmalab IPO Peer Comparison
The company can be compared with selected listed pharmaceutical companies based on business and industry characteristics.
| S. No. | Face Value | Company | P/E Ratio |
|---|---|---|---|
| 1 | ₹1 | Concord Biotech Limited | 61.07 |
| 2 | ₹2 | Divi’s Laboratories Limited | 87.80 |
| 3 | ₹1 | Cohance Lifesciences Limited | 95.02 |
| 4 | ₹2 | Laurus Labs Limited | 109.36 |
These companies operate in related pharmaceutical and life-sciences segments, although their business models and product portfolios may differ.
Strengths of Symbiotec Pharmalab IPO
The key positives associated with the company include its diversified API portfolio, international customer base, integrated manufacturing capabilities, and expansion into CDMO and complex injectable products. Its research-oriented approach and established pharmaceutical expertise also support its long-term business positioning.
Risks of Symbiotec Pharmalab IPO
Investors should also evaluate the risks before considering the Symbiotec Pharmalab Limited IPO. The company has significant exposure to API products and international markets. Changes in pharmaceutical regulations, quality requirements, export conditions, and customer concentration could affect business performance.
The concentration of manufacturing facilities in Madhya Pradesh also creates geographical exposure. Additionally, pharmaceutical businesses must continuously invest in research, technology, regulatory compliance, and manufacturing standards to remain competitive.
Symbiotec Pharmalab IPO Promoter Holding
| Particulars | Shareholding |
|---|---|
| Pre-Issue Shareholding | 36.41% |
| Post-Issue Shareholding | 33.28% |
The promoters include Anil Satwani, Kashish Satwani, Sushil Satwani, and Satwani Holdings LLP.
Click here to view the Greymarket Premium
Link : https://in.mpms.mufg.com/Initial_Offer/public-issues.html
Conclusion
The Symbiotec Pharmalab Limited IPO offers investors an opportunity to participate in a pharmaceutical company with established capabilities in APIs, steroidal products, CDMO services, and complex injectables. Its integrated manufacturing model, international customer base, research capabilities, and expanding product portfolio are important aspects to consider.
At the same time, investors should carefully assess pharmaceutical regulatory requirements, international market exposure, customer concentration, manufacturing concentration, valuation, and industry competition before making any investment decision. IPO information, financial figures, and market conditions can change, so investors should verify the latest official documents and disclosures before investing.
Disclaimer: This article is provided for informational and educational purposes only and should not be considered investment advice. IPO investments involve market risks, and investors should conduct their own research and consult a qualified financial professional before making investment decisions.
